Supernus Pharmaceuticals Operating Margin 2011-2024 | SUPN

Current and historical operating margin for Supernus Pharmaceuticals (SUPN) over the last 10 years. The current operating profit margin for Supernus Pharmaceuticals as of September 30, 2024 is 11.40%.
Supernus Pharmaceuticals Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2024-09-30 $0.65B $0.06B 9.20%
2024-06-30 $0.63B $0.03B 4.29%
2024-03-31 $0.60B $-0.01B -2.34%
2023-12-31 $0.61B $-0.01B -0.99%
2023-09-30 $0.61B $0.03B 4.75%
2023-06-30 $0.63B $0.02B 3.00%
2023-03-31 $0.67B $0.05B 7.19%
2022-12-31 $0.67B $0.05B 6.75%
2022-09-30 $0.66B $0.02B 2.58%
2022-06-30 $0.63B $0.05B 8.25%
2022-03-31 $0.60B $0.08B 12.48%
2021-12-31 $0.58B $0.09B 14.85%
2021-09-30 $0.56B $0.12B 21.81%
2021-06-30 $0.57B $0.15B 25.57%
2021-03-31 $0.56B $0.16B 28.37%
2020-12-31 $0.52B $0.17B 33.40%
2020-09-30 $0.48B $0.17B 36.06%
2020-06-30 $0.42B $0.16B 36.79%
2020-03-31 $0.40B $0.15B 38.06%
2019-12-31 $0.39B $0.15B 38.01%
2019-09-30 $0.41B $0.15B 36.27%
2019-06-30 $0.41B $0.15B 35.45%
2019-03-31 $0.40B $0.14B 34.16%
2018-12-31 $0.41B $0.14B 35.21%
2018-09-30 $0.38B $0.14B 36.22%
2018-06-30 $0.36B $0.12B 34.36%
2018-03-31 $0.33B $0.11B 33.83%
2017-12-31 $0.30B $0.10B 32.78%
2017-09-30 $0.28B $0.08B 29.35%
2017-06-30 $0.25B $0.08B 31.23%
2017-03-31 $0.23B $0.07B 28.38%
2016-12-31 $0.22B $0.05B 25.12%
2016-09-30 $0.20B $0.05B 23.35%
2016-06-30 $0.18B $0.03B 17.32%
2016-03-31 $0.16B $0.02B 14.11%
2015-12-31 $0.15B $0.02B 14.19%
2015-09-30 $0.14B $0.02B 13.33%
2015-06-30 $0.12B $0.01B 10.08%
2015-03-31 $0.11B $0.01B 10.62%
2014-12-31 $0.09B $-0.00B -5.38%
2014-09-30 $0.07B $-0.02B -29.17%
2014-06-30 $0.05B $-0.04B -74.00%
2014-03-31 $0.02B $-0.06B -280.00%
2013-12-31 $0.01B $-0.06B -554.55%
2013-09-30 $0.00B $-0.06B -3150.00%
2013-06-30 $0.00B $-0.06B -5800.00%
2013-03-31 $0.00B $-0.05B -5200.00%
2012-12-31 $0.00B $-0.04B -4200.00%
2012-09-30 $0.00B $-0.04B inf%
2012-06-30 $0.00B $-0.04B inf%
2012-03-31 $0.00B $-0.04B -3600.00%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00